AzTrials
AzTrials

DISTAL MALIGNANT BILIARY OBSTRUCTIONEUS-BDNCT04099862

Eus-giuded Biliary Drainage With Ec-lams vs ERCP as a Primary Intervention for Endoscopic Treatment of Patinets With Distal Malignant Biliary Obstruction

An observational study of DISTAL MALIGNANT BILIARY OBSTRUCTION, run by Istituto Clinico Humanitas at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Endoscopic retrograde cholangiopancreatography (ERCP) is the gold standard for the management of jaundice in patients with distal malignant biliary obstruction. However, surgically altered anatomy (i.e., Whipple intervention, Roux-en-Y gastric bypass, Billroth II surgery), periampullary diverticula, gastric outlet… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
DISTAL MALIGNANT BILIARY OBSTRUCTION
What is being tested?
ERCP and EUS-BD
Type of treatment
Surgery or procedure
How many people
220 participants
Where
1 siteItaly
Study dates
28 Feb 2021to 24 Jun 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with distal malignant biliary obstruction, who need endoscopic biliary drainage, will be randomized with a 1:1 ratio to undergo jaundice treatment by ERCP or EUS guided biliary drainage.

Who may be able to join

  • Age ≥18 years
  • Patients with distal malignant biliary obstruction
  • Abdominal ultrasound or computed tomography or magnetic resonance or EUS showing a dilated common bile duct > 15 mm diameter.
  • Agree to receive follow up phone calls
  • Able to provide written informed consent

Who cannot join

  • Coagulation and/or platelets hereditary disorders and/or INR>1.5, PLT<50,000.
  • Use of anticoagulants that cannot be discontinued
  • Pregnant women
  • Inability to sign the informed consent

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Endoscopy Unit, Humanitas Research Hospital

    Rozzano, Milano, 20089

Other trials in Italy

About this study

Endoscopic retrograde cholangiopancreatography (ERCP) is the gold standard for the management of jaundice in patients with distal malignant biliary obstruction. However, surgically altered anatomy (i.e., Whipple intervention, Roux-en-Y gastric bypass, Billroth II surgery), periampullary diverticula, gastric outlet obstruction, and malignant obstruction of the lumen determine the failure of the procedure in about 5-10% of cases, requiring alternative methods of decompression. Percutaneous transhepatic biliary drainage (PTBD) and surgical bypass are well established alternatives in these patients, but associated with increased morbidity, longer length of hospital stay and higher costs.

EUS guided biliary drainage (EUS-BD) through a transduodenal access is an alternative in cases of failed or unfeasible ERCP. EUS-BD has considerably evolved thanks to the development of dedicated devices such as lumen apposing metal stents (LAMS), specifically designed for endoscopic ultrasound procedures. LAMS are made up of braided nitinol that is fully covered with silicone to prevent tissue ingrowth, with wide flanges on both ends to provide anchorage.

Read more

Recently, LAMS have been incorporated into a delivery system with an electrocautery mounted on the tip (Hot Axios; Boston Scientific Corp.), which allows the device to be used directly to penetrate the target structure without the need to utilize a 19G needle, a guidewire, and a cystotome for prior dilation. This has been described for drainage of peri-pancreatic fluid collections, common bile duct (CBD), gallbladder, and for creation of gastro-jejuno anastomosis. The biliary drainage procedure performed with the Hot Axios sistem is a fast, one-step procedure that obviates the need accessory exchange and thus potentially reduces the risk of complications.

The procedure has been described as safe and effective with a technical success of 98.2%, clinical success of 96.4%, and low rate of complications 7% (consisting of duodenal perforations, bleeding and transient cholangitis).

Patients with distal malignant biliary obstruction have a higher risk of ERCP failure, related to the difficulty of bile duct cannulation or access to the second duodenal portion due to the presence of a stenosis. This condition could imply the need of more advanced cannulation techniques (such as pre-cut, Double Guide Wire DGW technique, pancreatic septotomy) with consequent higher risk of developing post ERCP pancreatitis (PEP). Unlike ERCP, an reaching the papilla is not a requisite for a successful EUS-BD. Moreover, since the papilla is not cannulated and the pancreatic duct is not accessed, this is expected to result in a minimal risk of post-procedural pancreatitis (about 0.50%).

The investigators hypothesize that, in patients with distal malignant biliary obstruction, EUS guided biliary drainage as first step approach has a lower risk of post-procedural pancreatitis compared to standard ERCP. The investoigators propose to perform a randomized controlled study to test this hypothesis.

Being tested
ERCP, EUS-BD

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ERCPProcedure or surgery

    Endoscopic retrograde cholangiopancreatography (ERCP)

  • EUS-BDProcedure or surgery

    Endoscopic UltraSound Biliary Drainage

Study groups in NCT04099862
Study groupRoleWhat they receive
ERCPEndoscopic retrograde cholangiopancreatography (ERCP)
Receives: Procedure: ERCP
EUS-BDEndoscopic UltraSound Biliary Drainage
Receives: Procedure: EUS-BD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of post-procedural acute pancreatitis

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2019
  2. Study start28 Feb 2021
  3. Primary completion30 Apr 2024
  4. Study completion24 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
220 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04099862
Sponsor's protocol ID
2339
Acronym
EUS-BD
Status last verified
Jul 2024
First submitted
19 Sep 2019
Last updated
6 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Anderloni A, Spadaccini M, Binda C, Mauro A, Stigliano S, Carrozza L, Colombo M, Mazza S, Coluccio C, Amato A, Andreozzi M, Maria Rizzo GE, Facciorusso A, Radaelli F, Carrara S, Mangiavillano B, Di Matteo FM, Tarantino I, Hassan C, Repici A, Fugazza A, Fabbri C. Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial. Gastroenterology. 2026 Mar;170(3):584-594. doi: 10.1053/j.gastro.2025.09.003. Epub 2026 Jan 9.

    PubMed 41511419

Questions about this trial

What is this clinical trial studying?

An observational study of DISTAL MALIGNANT BILIARY OBSTRUCTION, run by Istituto Clinico Humanitas at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of post-procedural acute pancreatitis (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04099862, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in